Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
50.90
+1.12 (2.25%)
At close: Aug 13, 2025, 4:00 PM
51.08
+0.18 (0.35%)
After-hours: Aug 13, 2025, 7:18 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.63
Revenue / Employee
4,032,864 DKK
Employees
77,349
Market Cap
227.37B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Thermo Fisher Scientific | 43.21B |
NVO News
- 5 hours ago - A Cure For Novo Nordisk - Seeking Alpha
- 8 hours ago - Novo Nordisk: The Falling Knife That Keeps Giving - Seeking Alpha
- 2 days ago - Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies? - Fast Company
- 2 days ago - Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes - Seeking Alpha
- 2 days ago - Novo Nordisk: Enough Is Enough - Seeking Alpha
- 2 days ago - Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities - Seeking Alpha
- 2 days ago - As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims? - Reuters
- 3 days ago - Why I Tripled My Novo Nordisk Position - Seeking Alpha